Basal insulin
Insulin degludec
INS_DEGLUDEC
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.00 (-1.40 to -0.58) | 0.55 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.80 (-1.50 to -0.08) | 0.46 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.89 (-1.33 to -0.41) | 0.50 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.84 (-1.30 to -0.36) | 0.50 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.23 (-0.23 to 0.75) | 0.36 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.24 (-1.42 to 1.04) | 0.47 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.27 (-1.77 to -0.63) | 0.53 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.37 (-2.54 to 0.83) | 0.59 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 1.05 (0.73 to 1.38) | 0.02 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 1.05 (0.71 to 1.38) | 0.03 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 3.73 (1.53 to 6.54) | 0.02 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 4.29 (-1.01 to 9.88) | 0.10 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.08 (0.47 to 3.64) | 0.16 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.32 (0.31 to 4.39) | 0.21 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 7.13 (2.42 to 12.43) | 0.00 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 6.17 (-1.24 to 13.11) | 0.02 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 1.74 (0.32 to 3.09) | 0.69 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 1.75 (0.36 to 3.02) | 0.70 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.34 (0.09 to 1.49) | 0.23 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide injection | OR 0.34 (0.10 to 1.65) | 0.22 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | OR 0.12 (0.04 to 0.59) | 0.02 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | OR 0.12 (0.04 to 0.54) | 0.01 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.15 (0.00 to 4.48) | 0.64 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.15 (0.00 to 5.22) | 0.59 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.95 (1.77 to 8.24) | 0.14 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.05 (1.61 to 9.46) | 0.14 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.43 (-2.91 to 1.89) | 0.27 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.29 (-3.06 to 2.53) | 0.32 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 8.66 (2.32 to 15.08) | 0.06 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.95 (-1.12 to 10.04) | 0.17 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 0.60 (-14.76 to 17.82) | 0.28 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 0.50 (-13.88 to 15.40) | 0.33 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.75 (0.52 to 1.08) | 0.65 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.75 (0.51 to 1.10) | 0.72 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.29 (0.10 to 0.71) | 0.89 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.30 (0.10 to 0.86) | 0.88 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.38 (0.22 to 0.65) | 0.89 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.40 (0.21 to 0.74) | 0.77 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.32 (0.11 to 0.81) | 0.90 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.34 (0.11 to 1.02) | 0.86 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.53 (0.35 to 0.80) | 0.88 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.54 (0.34 to 0.83) | 0.86 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.51 (0.23 to 1.07) | 0.81 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.55 (0.27 to 1.15) | 0.74 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.39 (0.03 to 5.16) | 0.63 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.41 (0.03 to 5.09) | 0.56 |
Trials
- SURPASS-3A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes2019 · 1,444 randomized · 52 weeks
- DUAL™ I ChinaA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)2017 · 720 randomized · 26 weeks
- DUAL™ II ChinaA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD2017 · 453 randomized · 26 weeks
- DUAL™ II JapanA Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs2016 · 210 randomized · 26 weeks
- DUAL™ I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus2015 · 819 randomized · 52 weeks
- DUAL™ IIA 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes2011 · 413 randomized · 26 weeks